Edition:
United Kingdom

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

3.56USD
7:09pm GMT
Change (% chg)

$-0.02 (-0.56%)
Prev Close
$3.58
Open
$3.56
Day's High
$3.73
Day's Low
$3.53
Volume
6,228
Avg. Vol
33,217
52-wk High
$5.11
52-wk Low
$1.90

Chart for

About

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $238.49
Shares Outstanding(Mil.): 50.53
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial

* MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL

11 Dec 2017

BRIEF-Fortress Biotech forms subsidiary Tamid Bio to develop novel aav gene therapies in Orphan Diseases

* FORTRESS BIOTECH FORMS SUBSIDIARY TAMID BIO TO DEVELOP NOVEL AAV GENE THERAPIES IN ORPHAN DISEASES WITH UNMET MEDICAL NEEDS Source text for Eikon: Further company coverage:

05 Dec 2017

BRIEF-Mustang Bio names new vice president of finance and corporate controller

* Mustang Bio announces appointment of Brian Achenbach as vice president of finance and corporate controller Source text for Eikon: Further company coverage:

14 Nov 2017

BRIEF-Fortress Biotech posts Q3 loss per share $0.67

* Fortress Biotech reports third quarter 2017 financial results and recent corporate highlights

09 Nov 2017

BRIEF-Fortress Biotech announces pricing of series a preferred stock offering

* Fortress Biotech Inc announces pricing of series a preferred stock offering

07 Nov 2017

BRIEF-Fortress Biotech proposes public offering of Series A preferred stock

* Fortress Biotech announces proposed public offering of Series A preferred stock Source text for Eikon: Further company coverage:

01 Nov 2017

BRIEF-Mustang Bio enters lease agreement for production of Car T therapies

* Entered lease agreement for manufacturing facility to support clinical development, commercialization of co's Car T product candidates​

30 Oct 2017

BRIEF-Fortress Biotech reports Q2 loss per share $0.43

* Fortress Biotech reports second quarter 2017 financial results and recent corporate highlights

09 Aug 2017

BRIEF-Fortress Biotech announces filing of provisional patent application for Caelum Biosciences' cael-101

* Fortress Biotech announces filing of provisional patent application for Caelum Biosciences' cael-101 Source text for Eikon: Further company coverage:

17 Jul 2017

BRIEF-Fortress Biotech says Lucy Lu, MD, appointed CEO of unit Avenue Therapeutics

* Fortress biotech announces appointment of lucy lu, md, as president and chief executive officer of subsidiary avenue therapeutics

03 Jul 2017

Competitors

Earnings vs. Estimates